Assorted News from the Last Week: CAC2 Supporting Member Day One Biopharmaceutical and Ipsen unveiled an ex-U.S. licensing agreement for tovorafenib (approved as Ojemda in

Assorted News from the Last Week: Congratulations to CAC2 Supporting Organization Day One Biopharmaceuticals and CAC2 member authors and reviewers who contributed to the white

Assorted News from the Last Week: Psychological and ethical issues raised by genomic testing in paediatric care pathway, a qualitative analysis with parents and childhood

Assorted News from the Last Week: Building a case for incorporating patient advocates throughout the research continuum in pediatric oncology. The NCI Council of Research

Assorted News from the Last Week: AWS is providing $10 million to accelerate research for pediatric health care and to better understand rare diseases, including

Assorted News from the Last Week: CAC2 Supporting Organization Member Day One Biopharmaceuticals announced it has entered into an exclusive licensing agreement with MabCare Therapeutics

Assorted News from the Last Week: Bristol Myers Squibb’s Augtyro (repotrectinib) has secured an accelerated approval from the FDA for the treatment of adult and

Assorted News from the Last Week: Research from the University of Birmingham could pave the way for using MRI scanning combined with machine learning to

Assorted News from the Last Week: The FDA granted accelerated approval to Eli Lilly And Co’s selpercatinib (Retevmo) for pediatric patients two years of age and

Assorted News from the Last Week: The FDA Pediatric ODAC met to “discuss perspectives on the impact of FDARA on the field of pediatric oncology,